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(MSMQ). METHODS: A subsection of the MSMQ was administered to MS patients 
currently not on DMT. They were asked questions about MS, using the health 
beliefs model as well as items regarding their perceptions of barriers to DMT 
initiation. All items were rated on a 1 to 5 scale, with 1 being “strongly disagree” 
and 5 being “strongly agree”. Patients who answered “agree” or “strongly agree” 
were combined for chi-square analysis; t-tests were used to compare mean 
scores. RESULTS: Ninety two MS patients reported being non-DMT users. The 
mean age was 58.6 years and 78.3% were female. Only 3.3% of non-DMT users 
agreed or strongly agreed that their MS would improve without treatment.  
The highest agreed upon perceptions of barriers to DMT use dealt with possible 
side effects (58.2%) and potential high cost (51.9%). Splitting the non-DMT  
users into those who never initiated DMT and those who used to take DMT 
revealed significant differences in the impression that physicians lack 
advocating DMT use (44.7% vs. 17.1%, respectively, p<0.01) and dislike for using 
needles (24.3% vs. 46.3%, respectively, p=0.043). CONCLUSIONS: MS patients who 
are not currently on DMT may not seek or re-seek treatment for various reasons. 
It appears certain perceptions regarding MS and DMT influence behavior in 
potential DMT use.  
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OBJECTIVES: To assess sensitivity of the EQ-5D to clinical change in patients 
with Parkinson’s disease with moderate to severe L-dopa induced dyskinesias. 
METHODS: Using data from a Phase IIB, randomized, 13-week, double-blind, 
placebo-controlled, dose-response study of AFQ056, a mGluR5 antagonist, we 
identified all patients with non-missing values for the modified Abnormal 
Involuntary Movement Scale (mAIMS) and the EQ-5D at baseline and week-9 
administrations. Patients were pooled across all six treatment groups (5 active 
drug, 1 placebo). Concurrent validity and responsiveness to clinical change were 
examined for the EQ-5D utility index (range -0.59 - 1.0, with 1 representing 
perfect health), visual analog scale (VAS) (range 0 - 100, with 100 representing 
perfect health), and individual item scores (ranging from no problems to major 
problems [3]), using the mAIMS (range 0 - 24, with 24 representing severe 
dyskinesias) as the criterion variable. RESULTS: Among 197 randomized subjects, 
149 (75.6%) had non-missing values for the EQ-5D and the mAIMS at baseline and 
week 9. The mean (SD) mAIMS total score at baseline was 13.5 (4.8); this measure 
was uncorrelated with all EQ-5D item responses. At week 9, however, mAIMS 
scores were generally higher for patients who reported more problems on EQ-5D 
item responses. While mAIMS scores improved by an average of 4.8 points 
between the baseline and week-9 assessments, the mean EQ-5D utility score and 
EQ-5D VAS improved by only 0.024 and 0.05, respectively, and the number with 
better EQ-5D item responses was approximately equal to the number with worse 
responses. CONCLUSIONS: The EQ-5D demonstrated limited concurrent validity 
in Parkinson’s disease patients with moderate to severe L-dopa induced 
dyskinesias, and the EQ-5D utility index and VAS were unresponsive to clinical 
change. Evidence to support use of the EQ-5D in this population remains 
inadequate.  
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OBJECTIVES: To ascertain the psychometric properties of EuroQol Five 
Dimensional Questionnaire (EQ-5D) among primary caregivers of children with 
autism. The convergent validity, discriminant validity, known-groups validity, 
internal consistency reliability, and floor and ceiling effects of EQ-5D were 
analyzed. METHODS: Using a cross-sectional online survey design, relevant 
study information was collected from 316 primary caregivers of children with 
autism. Study participants were from families of children with autism that were 
registered with the Interactive Autism Network (IAN). Convergent validity of the 
EQ-5D was assessed through its correlation with other measures of similar 
constructs. Discriminant validity was assessed by observing the correlation of 
EQ-5D domains with theoretically unrelated constructs. Known-groups validity 
was tested by comparing EQ-5D index and VAS scores across levels of autism 
severity among the care recipients. Reliability and floor and ceiling effects of the 
EQ-5D were also tested. RESULTS: More than 60% of participants reported 
problems of ‘anxiety/depression’. Convergent and discriminant validity of the 
EQ-5D was good. Significant correlation (convergent validity) was observed 
among EQ-5D index and VAS and (SF-12v2) Physical Component Summary (PCS) 
and Mental Component Summary (MCS) scores. Caregivers’ EQ-5D index and 
VAS scores varied by levels of autism severity among care recipients, providing 
evidence of known-groups validity. Reliability assessed through Cronbach’s 
alpha was less than satisfactory; however, corrected item-total correlations were 
adequate. Floor effects were absent, but ceiling effects were seen for EQ-5D index 
scores. CONCLUSIONS: To the best of our knowledge, this is the first study to 
test the psychometric properties of the EQ-5D among caregivers of children with 
autism. The EQ-5D is a psychometrically sound tool to elicit health state 
preferences among caregivers of children with autism.  
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OBJECTIVES: Health utility of caregivers of children with autism was assessed 
using the EuroQol five-dimensional questionnaire (EQ-5D). Utility scores of 
autism caregivers were compared to norms for the general adult United States 
(US) population. Predictors of health utility were identified. METHODS: A cross-
sectional online survey design was conducted. Caregivers registered with the 
Interactive Autism Network (IAN) were approached for participation in the 
online survey. Three hundred and sixteen usable responses were received. 
Health utility among caregivers was calculated and compared with the US 
population norms using Student’s t-test. Problems in EQ-5D domains and utility 
scores were analyzed by study characteristics using Kruskal-Wallis ANOVA. 
Ordinary least square regression using a fully adjusted multivariable model was 
used to determine the factors predicting health utility of autism caregivers. The 
Bruesh-Pagan test revealed presence of heteroskedasticity. To adjust for 
heteroskedasticity, White’s robust standard error estimates were reported. 
RESULTS: Roughly 94% of caregivers who participated in the study were females. 
As compared to their counterparts in the general US population, caregivers who 
were aged 18-44 years and were females had lower utility scores (P < 0.001). 
Significant differences in utility scores were observed among caregivers. When 
compared to males, females had lower health utility. Caregivers of lower 
socioeconomic status had lower utility scores and reported more problems in 
EQ-5D domains than those from higher socioeconomic status. Caregiver burden 
was inversely correlated with health utility. Caregiver physical and mental 
health status, objective strain, education, and relationship with the care 
recipient were found to significantly predict health utility (adjusted R-squared 
~57%). CONCLUSIONS: Autism caregivers had lower health utility than the 
general adult US population. Utility scores were found to vary by both caregiver 
and care recipient characteristics. There is an immediate need to address health 
concerns among this growing population.  
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OBJECTIVES: To evaluate the United States health-related quality-of-life burden 
of multiple sclerosis (MS) as compared to other debilitating chronic conditions 
using nationally representative data from the Medical Expenditure Panel Survey 
(MEPS). METHODS: We identified a sample of non-institutionalized patients aged 
≥18 with MS (ICD-9 code 340) using MEPS data (1998-2009) and compared them to 
individuals without MS. Similarly, cohorts were generated for the following 
common debilitating chronic conditions and their respective non-condition 
control cohorts: rheumatoid arthritis (ICD-9 code 714.0), diabetes (ICD-9 code 
250.0 – 250.93), inflammatory bowel disease (ICD-9 code 555), depressive disorder 
(ICD-9 code 311), acute coronary syndrome (ICD-9 code 411.1), and asthma (ICD-9 
code 493). The incremental changes for condition versus control were estimated 
for the 12-item Short Form Health Survey (SF-12) physical and mental summary 
scores, and the SF-6D, a preference (utility) measurement adaptation of the Short 
Form-36 questionnaire. We used ordinary least squares regression (separate 
model for each chronic condition versus control comparison) and included 
adjustment for gender, race, ethnicity, region, age, insurance status, education, 
number of chronic conditions other than the analyzed chronic condition, and 
survey year. RESULTS: As compared to other debilitating chronic conditions, the 
adjusted decrement in the SF-12 physical summary score was highest for MS  
(-11.89), followed by rheumatoid arthritis (-7.23), and inflammatory bowel 
disease (-3.94). The adjusted decrement in the SF-12 mental summary score for 
MS was (-2.9), second only to depression (-8.9). The adjusted SF-6D preference 
score deduction was highest for MS (-0.11), followed by depression (-0.10) and 
rheumatoid arthritis (-0.07). The p-values were <0.05 for all listed decrements 
compared to the control cohorts. CONCLUSIONS: MS is associated with the 
lowest HRQoL compared to other debilitating chronic conditions, with the 
exception of depression on the SF-12 metal summary score, demonstrating the 
extreme burden this disease places on the patient and society.  
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OBJECTIVES: To evaluate, from patients’ perspective, the relative importance of 
attributes related to epilepsy and the AEDs used to treat it, as well as the role of 
those attributes on adherence behaviour and quality of life (QoL). METHODS: 
Patients with epilepsy from seven countries completed a discrete choice 
experiment online choosing between AEDs with varying attributes including 
concentration problems, mood changes, balance problems, sleepiness, weight 
gain, seizure frequency, and out of pocket cost. These six attributes were 
identified for inclusion through a review of the literature and product labels. 
Attribute levels were combined in an orthogonal design. Respondents also 
completed three instruments measuring QoL, health state utility (HSU) and 
medication adherence: QOLIE-31-P, EQ-5D-5L, and MMAS-8, respectively. Tri-
level attributes were transformed to a continuous scale. Choice data were 
analysed using a mixed-logit model. Willingness to pay was estimated through 
marginal rates of substitution and using purchasing power parities. Regression 
methods explored the association between preferences, QoL, and adherence. 
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RESULTS: Patients (n=660, 100% completion rate) completed the survey. All 
attributes were significant predictors of choice except sleepiness. Respondents 
were significantly more likely to choose a treatment that provided a 10% 
reduction in seizure frequency (Odds Ratio [OR]=1.75, 95% CI 1.68-1.82) or avoided 
weight gain (3lb) (OR=0.751, 95% CI=0.731-0.772). Respondents were willing to pay 
an additional £39 and £20 per month for AEDs with those attributes. 
Furthermore, respondents who become unresponsive during a seizure placed 
higher levels of preference on an AED that would reduce seizure frequency. 
Respondents who reported higher levels of adherence to their AEDs (MMAS-8) 
reported better quality of life (QoL) (QOLIE-31-P and EQ-5D-5L). CONCLUSIONS: 
Seizure reduction is the most important AED attribute to epilepsy patients, but 
lack of weight gain is also valued. Higher adherence to AEDs appears to be linked 
with improved QoL.  
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OBJECTIVES: Disease modifying therapies (DMTs) decrease relapses in patients 
with multiple sclerosis (MS). Due to their wide variety of risk/benefit attributes, 
patients must weigh their preferences when choosing DMTs. We determine 
patient preferences for DMTs risk/benefit attributes. METHODS: Our choice-
based conjoint (CBC) survey developed using Sawtooth software was given in-
person, to 300 consenting adults with relapsing remitting MS at University of 
California, San Francisco’s MS clinic. Each patient answered 16 choice tasks. 
They chose one of two choices with 3-4 different levels of 6 risk and benefit 
attributes of hypothetical DMTs. Benefits included delayed progression, reduced 
relapses, and symptom improvement. Risks were mild side effects (SEs), serious 
SEs, and administration route and frequency. Analysis used mixed-effects 
logistic regression. RESULTS: Patients were 76% female; 75% with mild, 18% 
moderate, and 7% severe disease. All 6 attributes significantly impacted patient 
preference. Of the benefits, the preferences were highest for preventing 
progression 10 vs 2 years (odds ratio [OR]=2.27, p<0.001) and for substantial vs no 
improvement in symptoms (OR=3.67, p<0.001). Patients may be willing to accept 
a 0.05-0.1% risk of serious SEs leading to death (OR=0.57-0.66; p<0.001) to gain a 
moderate to substantial benefit from their therapy. A 1% risk of serious SE 
compared to no risk (OR=0.22, p<0.001) resulted in very low preference, but had a 
comparable magnitude in preference to a substantial improvement in symptoms 
vs no improvement (OR=1.60, p<0.001). Compared to daily subcutaneous 
administration, patients preferred daily oral administration (OR=2.15, p<0.001), 
then monthly intravenous (OR=1.54, p<0.001), and then intramuscular weekly 
(OR=1.19, p<0.01). CONCLUSIONS: Patients are willing to make risk/benefit 
tradeoffs in medication selection. Patient prefer treatments that delay 
progression or improve symptoms to those that prevent relapses (the primary 
outcomes of many clinical trials). Oral and monthly administration is preferred.  
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OBJECTIVES: Insomnia - defined as a difficulty in initiating or maintaining sleep 
– is known to accompany chronic diseases as comorbidity. Nevertheless, the 
impact of insomnia - as a comorbidity of overactive bladder and incontinence- 
on overall burden of illness is unclear. The objective of our study was thus to 
analyze the impact of insomnia as comorbidity of urological diseases on burden 
of illness of over a five year period. METHODS: In 2007, two representative adult 
samples of the Kantar Health European Healthcare Panel in Germany and UK 
were surveyed (n=72.605) and self-reports about insomnia, overactive bladder 
and incontinence were collected. In 2012, a subsample of 4.008 individuals was 
re-contacted and participants completed a general health, functional status  
and work disability questionnaire. RESULTS: In 2007, 3.2% of the initial 
representative sample reported overactive bladder, and 6.9% incontinence. A 
total of 38.9% of the individuals with one or both of these problems also suffered 
from insomnia. Five years later, in 2012, 26.1% of the entire group of individuals 
with one or both of the urological diseases indicated very good or excellent 
health, 45.9% experienced functional limitations and 28.1% suffered from work 
disability. In the subgroup of individuals with urological diseases in combination 
with insomnia, the percentage of individuals with very good/excellent health 
dropped to 15.2%, functional limitations increased to 61%, and 41.7% persons 
were disabled at their workplace. CONCLUSIONS: As these results demonstrate, 
insomnia is an important comorbidity of urological diseases and intensifies 
related burden of illness and reduces work related performance. Insomnia 
should be considered for inclusion into appropriate treatment strategies for 
urological diseases.  
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OBJECTIVES: To review disease- and condition-specific QoL instruments and 
their psychometric properties in Parkinson’s disease (PD), treatment options, and 
caregiver burden (CB). METHODS: A systematic literature search was conducted 
among peer-reviewed journals from January 2008 to December 2012 on quality of 
life (QoL) of PD patients or patients undergoing drug therapy in electronic 
databases such as Pubmed, PsycINFO, CINAHL, and Cochrane. A full review was 
conducted on articles that met the inclusion criteria. The search was limited to 
English language, full text availability, humans, and within five years; however, 
no time-frame was stipulated for CB. Meta-analyses, systematic reviews, or 
studies conducted exclusively outside the United States were excluded. For 
studies assessing CB, instruments not validated in PD population were excluded. 
RESULTS: The review identified seven disease-specific and two generic 
instruments assessing QoL in PD, 13 instruments recommended by the 
Movement Disorder Society in assessing QoL in patients undergoing drug 
therapy, and 12 instruments that assessed CB. A description of the domains, 
scaling, and psychometric properties of the instruments were included. 
Instruments ranged from comprehensive scales assessing all aspects of PD to 
recently developed instruments designed to assess a specific component of PD 
such as “wearing off” periods or freezing of gait. In PD patients undergoing drug 
therapy, four studies were identified that assessed patients in early PD and two 
studies focused on levodopa-induced motor fluctuations. Common domains 
assessed by the CB instruments were clinical, socio-demographic, emotional, 
and functional factors. Overall, Unified Parkinson’s Disease Rating Scale and 
Zarit Caregiver Burden Inventory were the most widely used instruments. 
CONCLUSIONS: Multiple factors contribute to the QoL in PD patients and their 
caregivers including disease severity, unpredictable disease progression, and 
adverse effects of treatment. This review highlights the instruments and their 
properties in PD and serves as a useful resource for researchers and clinicians.  
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OBJECTIVES: Using data from the Medical Expenditure Panel Survey (MEPS), we 
assessed quality-of-life (QoL) scores associated with insomnia and hypnotic use. 
METHODS: Dependent variables were the mental component summary (MCS) 
and physical component summary (PCS) scores from the 12-item Short-Form 
Health Survey (SF-12). These summary scores are standardized to 1998 
population norms (mean = 50; SD = 10). Multivariate regression analyses were 
used to compare cohorts while controlling for demographic and clinical 
characteristics. RESULTS: Of 104,274 adults in MEPS from 2005 through 2009, 
about 1.4% (n = 1,401) had a diagnosis of insomnia. Among those with a 
diagnosis, 45.6% (n = 639) used a prescription hypnotic. The mean PCS scores 
were 9.2 points lower for subjects with insomnia than without insomnia (PCS: 
40.6 ± SE0.5; PCS: 49.8 ± SE0.1, p < 0.001), while the mean MCS scores were 6.9 
points lower between the two groups (MCS: 44.1 ± SE0.1, MCS = 51.0 + SE0.1; p < 
0.001). After controlling for demographic and clinical characteristics, the 
difference remained significant (PCS: 5.1 points lower; MCS: 6.2 points lower; 
p<0.001). There was no difference in mean scores for insomnia patients who 
used hypnotics (n = 639; PCS: 40.6 ± SE0.8; MCS: 44.3 ± SE0.6) compared to those 
not using hypnotics (n = 762; PCS: 40.6 ± SE0.7, MCS: 43.9 ± SE0.5). 
CONCLUSIONS: Although patients with a diagnosis for insomnia had 
significantly lower physical and psychological QoL summary scores compared to 
those without this diagnosis, differences were not seen for those with a 
diagnosis and a prescription hypnotic compared to those with a diagnosis and no 
prescription hypnotic. Regression was used to control for differences in cohorts, 
but selection bias may still be a concern. Using a ‘before and after therapy’ 
design, with patients serving as their own controls is an important next step.  
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OBJECTIVES: Multiple sclerosis (MS) burdens not only the patients but also their 
caregivers. Caregivers have been described as “hidden patients” and they often 
experience social, psychological, emotional, and economic hardships. The study 
goal is to provide a comprehensive review of the instruments along with their 
psychometric properties that measure caregiver burden in MS. METHODS: A 
systematic literature search was conducted among peer-reviewed journals from 
2002-2012 in the databases PubMed, Cochrane Review, PsycINFO, and Medline to 
identify instruments that measured caregiver burden in MS. In addition, the 
review also evaluated the instrument’s psychometric properties such as 
reliability and validity. Clinical and review studies were excluded from the 
review. RESULTS: A total of nine caregiver burden instruments were identified 
that were utilized in MS population. The instruments varied widely with respect 
to items and domains, administration, scaling and scoring. The number of items 
and domains in the instruments ranged from 1-7 and 9-29, respectively. All the 
instruments displayed adequate psychometric properties. The Zarit Burden 
Interview scale has been extensively used to measure caregiver burden in MS in 
numerous countries. The scale measures the domains of health, psychology, 
finance and social, and adequately gauges the possible facets that MS caregivers 
typically experience. The scale is reliable and valid with an internal consistency 
ranging between 0.70 and 0.93, test re-test reliability of 0.71, and an intra-class 
correlation of 0.89. CONCLUSIONS: The importance of measuring caregiver 
burden in MS has been recognized and researched in several countries. 
Interestingly, there is a dearth of studies conducted in the United States. 
Caregiver burden in MS should be assessed due to the multi-dimensional threat 
it imposes on caregivers. The assessment of caregiver burden can assist 
